Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
18F-SiTATE
- Development stage
- Preclinical
- Lead developer
- Universitat Heidelberg
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
18F-SiTATE (also known as [18F]SiFAlin-TATE) is a novel fluorine-18 labeled somatostatin receptor (SSTR)-targeting peptide radiopharmaceutical developed for positron emission tomography (PET) imaging. It consists of a silicon-fluoride acceptor (SiFA) moiety conjugated to [Tyr3]-octreotate (TATE) via a hydrophilic linker. 18F-SiTATE exhibits high selectivity and affinity for somatostatin receptor subtype 2 (SSTR2), which is overexpressed in various neuroendocrine neoplasms (NENs), meningiomas, thyroid carcinomas, and pheochromocytomas/paragangliomas. Labeled with fluorine-18, 18F-SiTATE offers significant logistical and imaging advantages over traditional gallium-68-labeled somatostatin analogs, including a longer physical half-life (approximately 110 minutes) that allows for cyclotron-based batch production and distribution, as well as superior spatial resolution and high tumor-to-background contrast.
- Other names
- [18F]SiFAlin-TATE[18F]SiTATE18F-SiFAlin-TATEsiFAlin-TATEsiTATE
02
Targets
SSTR2 (Somatostatin receptor type 2)
Beyond the preview
Go deeper on 18F-SiTATE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 18F-SiTATE.